These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 9737640)

  • 1. Current and future treatment of hyperlipidemia: the role of statins.
    Farnier M; Davignon J
    Am J Cardiol; 1998 Aug; 82(4B):3J-10J. PubMed ID: 9737640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies.
    Davignon J; Hanefeld M; Nakaya N; Hunninghake DB; Insull W; Ose L
    Am J Cardiol; 1998 Aug; 82(4B):32J-39J. PubMed ID: 9737644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of protease inhibitor-associated hyperlipidemia.
    Penzak SR; Chuck SK
    Am J Cardiovasc Drugs; 2002; 2(2):91-106. PubMed ID: 14727985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitors.
    Lopez LM
    Am J Health Syst Pharm; 2002 Jun; 59(12):1173-9; quiz 1180-2. PubMed ID: 12073858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Statins: similarities and differences in the pharmacological, clinical and laboratory aspects].
    Motti C; Gnasso A; Cortese C
    Ann Ital Med Int; 2000; 15(1):96-102. PubMed ID: 10842898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolving role of statins in the management of atherosclerosis.
    Vaughan CJ; Gotto AM; Basson CT
    J Am Coll Cardiol; 2000 Jan; 35(1):1-10. PubMed ID: 10636252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Atherosclerosis in light of the evidence from large statin trials].
    Cortese C; Bernardini S; Motti C
    Ann Ital Med Int; 2000; 15(1):103-7. PubMed ID: 10842899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
    Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG; Paterson JR
    QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Statins and diabetic hyperlipidemia].
    Vergès B
    Ann Endocrinol (Paris); 2001 Feb; 62(1 Pt 2):128-32. PubMed ID: 11240415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety.
    Stein E
    Am J Cardiol; 1998 Aug; 82(4B):40J-46J. PubMed ID: 9737645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.
    Rosenson RS; Tangney CC
    JAMA; 1998 May; 279(20):1643-50. PubMed ID: 9613915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggressive lipid therapy in the statin era.
    Farmer JA
    Prog Cardiovasc Dis; 1998; 41(2):71-94. PubMed ID: 9790411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
    Perreault S; Hamilton VH; Lavoie F; Grover S
    Cardiovasc Drugs Ther; 1997 Jan; 10(6):787-94. PubMed ID: 9110123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol.
    Sotiriou CG; Cheng JW
    Ann Pharmacother; 2000 Dec; 34(12):1432-9. PubMed ID: 11144702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.